Literature DB >> 9662752

Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus.

R H Derksen1.   

Abstract

OBJECTIVE: This study was performed to evaluate in vivo and in vitro data on the effects of the adrenal steroid dehydroepiandrosterone (DHEA) with emphasis on its potential use in the treatment of systemic lupus erythematosus (SLE).
METHODS: The literature dealing with DHEA was reviewed.
RESULTS: Initially, research on DHEA focused on effects of DHEA in relation to obesity. Over the past decade, research stimulated by associations between the physiological decline in DHEA and aging, cardiovascular disease, changes in metabolism, brain function, and immune senescence have generated insight into the many effects that DHEA or its metabolites may have. In SLE a role for sex hormones in both the etiopathogenesis and disease activity is recognized. In SLE, as in aging, low DHEA levels are frequently found, especially with corticosteroid treatment.
CONCLUSIONS: Research data in the elderly, on both hormonal and immunologic effects, suggest that DHEA may become an adjunctive treatment for SLE patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662752     DOI: 10.1016/s0049-0172(98)80013-9

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  10 in total

1.  Fatigue in systemic lupus erythematosus.

Authors:  Grace E Ahn; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2012-04-01

Review 2.  Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus.

Authors:  R Furie
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 3.  Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review.

Authors:  Hon K Yuen; Melissa A Cunningham
Journal:  Ther Clin Risk Manag       Date:  2014-10-01       Impact factor: 2.423

Review 4.  Newer drugs for the treatment of lupus nephritis.

Authors:  Dudy G Kuiper-Geertsma; Ronald H W M Derksen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Mental wellbeing and quality of sexual life in women with primary Sjögren's syndrome are related to circulating dehydroepiandrosterone sulphate.

Authors:  S Th Valtysdottir; L Wide; R Hallgren
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 6.  Immunomodulators in SLE: Clinical evidence and immunologic actions.

Authors:  L Durcan; M Petri
Journal:  J Autoimmun       Date:  2016-06-28       Impact factor: 7.094

7.  A novel dehydroepiandrosterone analog improves functional recovery in a rat traumatic brain injury model.

Authors:  Amir S Malik; Raj K Narayan; Woodrow W Wendling; Russell W Cole; Laura L Pashko; Arthur G Schwartz; Kenneth I Strauss
Journal:  J Neurotrauma       Date:  2003-05       Impact factor: 5.269

8.  Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment.

Authors:  Tina B McKay; Jesper Hjortdal; Henrik Sejersen; John M Asara; Jennifer Wu; Dimitrios Karamichos
Journal:  Sci Rep       Date:  2016-05-09       Impact factor: 4.379

Review 9.  Dehydroepiandrosterone for systemic lupus erythematosus.

Authors:  D Crosbie; C Black; L McIntyre; P L Royle; S Thomas
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 10.  The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview.

Authors:  Justine Tang; Li-Ru Chen; Kuo-Hu Chen
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.